Fidah bin Ismail Alsagoff
Direktor/Vorstandsmitglied bei Tychan Pte Ltd.
Profil
Fidah bin Ismail Alsagoff currently works at Tychan Pte Ltd., as Director.
Aktive Positionen von Fidah bin Ismail Alsagoff
Unternehmen | Position | Beginn |
---|---|---|
Tychan Pte Ltd.
Tychan Pte Ltd. BiotechnologyHealth Technology Tychan Pte Ltd. is a clinical-stage biotechnology company based in Singapore that focuses on developing life-saving treatments for emerging infections through disruptive technologies. Tychan was founded by Professor Ram Sasisekharan of Massachusetts Institute of Technology (MIT)/Singapore MIT Alliance for Research and Technology (SMART) and Professor Ooi Eng Eong of Duke-National University of Singapore (Duke-NUS) Medical School, both of whom have expertise in biologics development and biology of acute viral infections. The private company is based in Singapore, Singapore, and Randall E. Woods has been the CEO of the company since 2021. The Singaporean company works closely with regulatory authorities to accelerate the translation from non-clinical studies to clinical trials for emerging pathogens. Temasek Holdings is the founding investor of Tychan. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Tychan Pte Ltd.
Tychan Pte Ltd. BiotechnologyHealth Technology Tychan Pte Ltd. is a clinical-stage biotechnology company based in Singapore that focuses on developing life-saving treatments for emerging infections through disruptive technologies. Tychan was founded by Professor Ram Sasisekharan of Massachusetts Institute of Technology (MIT)/Singapore MIT Alliance for Research and Technology (SMART) and Professor Ooi Eng Eong of Duke-National University of Singapore (Duke-NUS) Medical School, both of whom have expertise in biologics development and biology of acute viral infections. The private company is based in Singapore, Singapore, and Randall E. Woods has been the CEO of the company since 2021. The Singaporean company works closely with regulatory authorities to accelerate the translation from non-clinical studies to clinical trials for emerging pathogens. Temasek Holdings is the founding investor of Tychan. | Health Technology |